06.30.11
Robinson Pharma Inc. (RPI) has introduced ARTcaps, a patent-pending technology capable of producing clear enteric softgels that feature acid resistance, enhanced moisture tolerance and greater shell robustness. The new technology creates a gel polymer structure that resists stomach acid to facilitate the delayed release of the capsules’ active ingredients. ARTcaps is a diversified technology that can produce clear or colored softgels that comply with the USP standard for enteric release and can be manufactured on RPI’s state-of-the-art, continuous drying production lines. The new gel polymer structure is applicable to a wide variety of fill materials and does not require additional processing after encapsulation like other enteric softgels. Initial plans for ARTcaps product applications will be for nutritional products, specifically high strength omega 3 concentrates. Future plans include markets other than the dietary supplement space that RPI has typically served. For further information: www.robinsonpharma.com
